HYPR — Hyperfine, Inc.

Is HYPR overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Strong Oversold As of November 17, 2026

Hyperfine, Inc. (HYPR) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $0.61. The rating moved from Oversold to Strong Oversold on November 13, 2026.

See all oversold Healthcare stocks →

AI analysis

Hyperfine, Inc. (HYPR) faces a challenging near-term outlook driven by constrained liquidity, limited commercial adoption of its portable MRI technology, and unfavorable sector flows that favor larger, defensive healthcare names. Absent clear evidence of accelerating placements, sustainable reimbursement, or a near-term non‑dilutive financing solution, downside pressure and dilution risk are the primary near-term scenarios. Key monitors: cash runway and financing terms, month‑over‑month deployment metrics, any material partnerships or reimbursement wins, and any regulatory or clinical-readout developments.

Key factors

  • Weak near-term liquidity profile and likely ongoing cash burn typical of small-cap medical-device developers without broad commercial adoption
  • Limited commercial traction and slow enterprise adoption for point-of-care MRI solutions relative to incumbent imaging modalities
  • Macro and sector flows favor large-cap defensive pharma and diagnostics, reducing investor appetite for early-stage device names
  • Convertible-debt and financing pressure in mid‑cap diagnostics/biotech creates a tougher funding environment and potential dilution risks for similar issuers
  • Low social and research visibility combined with limited recent filings or news increases information asymmetry and makes the stock prone to volatility

Risks

  • Acute funding risk leading to dilutive equity raises or distress if revenue ramp underperforms expectations
  • Slower reimbursement adoption or limited hospital/clinic capital spending reducing device placements
  • Competitive pressure from established imaging vendors and potential new portable imaging entrants
  • Regulatory setbacks or device-related safety issues that could delay or restrict commercial rollout
  • High share‑price volatility and low liquidity raising the chance of sharp downside moves independent of fundamentals

See today's live rating, score and targets

Members see the live hourly rating for HYPR — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.